SHANG.FOS.PHARM.GR.H YC 1 (08HH) - Total Assets
Based on the latest financial reports, SHANG.FOS.PHARM.GR.H YC 1 (08HH) holds total assets worth €122.97 Billion EUR (≈ $143.76 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SHANG.FOS.PHARM.GR.H YC 1 (08HH) net assets for net asset value and shareholders' equity analysis.
SHANG.FOS.PHARM.GR.H YC 1 - Total Assets Trend (2021–2025)
This chart illustrates how SHANG.FOS.PHARM.GR.H YC 1's total assets have evolved over time, based on quarterly financial data. Check 08HH financial resilience to evaluate the company's liquid asset resilience ratio.
SHANG.FOS.PHARM.GR.H YC 1 - Asset Composition Analysis
Current Asset Composition (December 2025)
SHANG.FOS.PHARM.GR.H YC 1's total assets of €122.97 Billion consist of 28.2% current assets and 71.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.9% |
| Accounts Receivable | €9.36 Billion | 7.8% |
| Inventory | €6.25 Billion | 5.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €19.94 Billion | 16.6% |
| Goodwill | €10.81 Billion | 9.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SHANG.FOS.PHARM.GR.H YC 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SHANG.FOS.PHARM.GR.H YC 1 market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SHANG.FOS.PHARM.GR.H YC 1's current assets represent 28.2% of total assets in 2025, a decrease from 32.6% in 2021.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2025, down from 11.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 24.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 16.6% of total assets.
SHANG.FOS.PHARM.GR.H YC 1 Competitors by Total Assets
Key competitors of SHANG.FOS.PHARM.GR.H YC 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
SHANG.FOS.PHARM.GR.H YC 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 0.97 | 0.93 |
| Quick Ratio | 0.76 | 0.78 | 0.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-2.62 Billion | €-1.06 Billion | €-2.60 Billion |
SHANG.FOS.PHARM.GR.H YC 1 - Advanced Valuation Insights
This section examines the relationship between SHANG.FOS.PHARM.GR.H YC 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.88 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 2.2% |
| Total Assets | €120.05 Billion |
| Market Capitalization | $1.19 Billion USD |
Valuation Analysis
Below Book Valuation: The market values SHANG.FOS.PHARM.GR.H YC 1's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: SHANG.FOS.PHARM.GR.H YC 1's assets grew by 2.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
The table below shows the annual total assets of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €120.05 Billion ≈ $140.36 Billion |
+2.21% |
| 2024-12-31 | €117.46 Billion ≈ $137.32 Billion |
+3.52% |
| 2023-12-31 | €113.47 Billion ≈ $132.66 Billion |
+5.88% |
| 2022-12-31 | €107.16 Billion ≈ $125.29 Billion |
+14.85% |
| 2021-12-31 | €93.31 Billion ≈ $109.08 Billion |
-- |
About SHANG.FOS.PHARM.GR.H YC 1
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more